MindMed Shareholders Vote For All Six Company Nominees At Annual Meeting, Current R&D Path Upheld

MindMed’s MNMD heated proxy battle over R&D strategy might finally be coming to an end. On Wednesday, June 21, the company announced a preliminary vote assessment that showed shareholders elected all six of its nominees at the annual meeting.

As stated by the psychedelics biotech company, a quorum was present at the annual meeting, and the number of shares represented exceeded 40% of the total outstanding shares entitled to vote.

Following suit, CEO Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs and Carol A. Vallone would comprise MindMed’s new board of directors.

MindMed’s CEO and director Robert Barrow thanked both the company’s shareholders “for their support and engagement throughout this process” and independent proxy advisory firms Institutional Shareholder Services (ISS) and Glass, Lewis & Co. “for their recommendations, which validated our strategy and the quality of our directors.” 

Further, Barrow stated the board is “fully committed to the company’s success as we navigate this pivotal period,” referring to the two key clinical readouts expected later this year. 

See also: 80 Years Post-Discovery, LSD Shows Significant Potential For Major Depression In Advanced Clinical Trial

“We are glad to put this proxy contest behind us and fully focus on bringing our transformative therapies to market in order to help patients in need and deliver value for all shareholders,” he concluded.

Final results will be filed on a Form 8-K with the U.S. SEC as well as with the Canadian securities regulatory authorities.

Photo: Benzinga edit with photo by Raimundo79 and Blue Planet Studio on Shutterstock.